These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35245886)

  • 1. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
    Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
    Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 4. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance.
    Ventelä S; Sittig E; Mannermaa L; Mäkelä JA; Kulmala J; Löyttyniemi E; Strauss L; Cárpen O; Toppari J; Grénman R; Westermarck J
    Oncotarget; 2015 Jan; 6(1):144-58. PubMed ID: 25474139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
    Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
    Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
    Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
    Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
    Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRPM7 via calcineurin/NFAT pathway mediates metastasis and chemotherapeutic resistance in head and neck squamous cell carcinoma.
    Chen TM; Huang CM; Hsieh MS; Lin CS; Lee WH; Yeh CT; Liu SC
    Aging (Albany NY); 2022 Jun; 14(12):5250-5270. PubMed ID: 35771152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
    Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
    Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
    J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L.
    Nathansen J; Lukiyanchuk V; Hein L; Stolte MI; Borgmann K; Löck S; Kurth I; Baumann M; Krause M; Linge A; Dubrovska A
    Oncogene; 2021 Jun; 40(24):4214-4228. PubMed ID: 34079088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of RIPK1 and FADD are associated with chemosensitivity and survival in head and heck squamous cell carcinoma via tanshinone IIA-mediated modulation of the RIPK1-FADD-Caspase 8 complex.
    Shen B; Han W; Tan X; Gu KJ; Naseem DF; Zheng G; Li G; Lou J; Chen C
    Mol Carcinog; 2024 Jul; 63(7):1406-1416. PubMed ID: 38695620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
    Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
    PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.
    Khedkar HN; Chen LC; Kuo YC; Wu ATH; Huang HS
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
    Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
    Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
    Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
    Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment.
    Wang YF; Chang CJ; Chiu JH; Lin CP; Li WY; Chang SY; Chu PY; Tai SK; Chen YJ
    Oncotarget; 2014 Sep; 5(17):7392-405. PubMed ID: 25277180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.